End-Capped Polymeric Guanidine Biocide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymeric guanidines lack suitability due to high mammalian and aquatic toxicity, endocrine disrupting properties, and slow biodegradation, making them non-viable for modern biocidal and medical applications under current regulatory standards.
Innovation Solution
A polycondensation product is synthesized using an oxyalkylene diamine, an alkylene diamine, and a guanidine or its salt, with an additional end-capping agent step to minimize terminal amino groups, reducing cytotoxicity and endocrine disrupting properties while maintaining antimicrobial efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polymeric guanidines are used as biocidal active substances, then antimicrobial efficacy is achieved, but mammalian and aquatic toxicity increases and endocrine disrupting properties occur
Solution Approach 1:
The patent changes the chemical structure parameters of polymeric guanidines by introducing oxyalkylene groups (polyethylene glycol or polypropylene glycol) into the polymer chain. This structural modification reduces mammalian and aquatic toxicity while preserving antimicrobial efficacy, directly resolving the contradiction between effectiveness and safety.
Solution Approach 2:
The invention creates composite polymeric structures combining guanidine units with oxyalkylene segments. This composite approach allows the material to maintain the biocidal properties of guanidine while incorporating the biocompatible characteristics of polyethylene glycol or polypropylene glycol, thus reducing toxicity.
2Reliability
If conventional polymeric guanidines are used, then biocidal activity is achieved, but biodegradation rate decreases
Solution Approach 1:
The patent modifies the chemical composition by incorporating oxyalkylene segments that contain oxygen atoms in the polymer backbone. This structural change enhances the biodegradability of the polymer by making it more susceptible to microbial attack and enzymatic breakdown, while maintaining the biocidal activity of the guanidine groups.
3Stability of the object's composition
If end-capping agents with primary alkyl amine groups are used, then polymer stability is improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the functional group at the polymer chain ends from primary alkyl amine groups to hydroxyl groups or other non-toxic groups. This modification reduces cytotoxicity while maintaining polymer stability through alternative end-capping mechanisms that do not rely on reactive primary amines.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting product exhibits lower cytotoxicity, reduced endocrine disrupting activity, and faster biodegradation, meeting modern regulatory requirements for biocidal and medical applications with enhanced antimicrobial efficacy.
Implementation Method 1
a polycondensation product synthesized using an oxyalkylene diamine, an alkylene diamine, and a guanidine or its salt
Data Source
AI summary
An embodiment relates to a substance comprising an end-capped amino compound comprising an amino compound and at least a portion of an end capping agent, wherein the at least the portion of the end capping agent contains no primary alkyl amine group and wherein the substance exhibits no activity as measured by: (a) a Cytotox CALUX assay; (b) a Steroidogenesis ERα CALUX assay; (c) a AR CALUX assay; (d) a Anti ERrα CALUX assay; (e) a Steroidogenesis AR CALUX assay; (f) an anti-AR CALUX assay; (g) a TRβ CALUX assay; (h) a anti-TRβ CALUX assay; (i) a TTR-TRβ CALUX assay; or (j) a TPO assay.